Total Payments
$36,931
2024 Payments
$35,552
Companies
14
Transactions
83
Medicare Patients
77
Medicare Billing
$10,369
Payment Breakdown by Category
Other$23,853 (64.6%)
Travel$11,180 (30.3%)
Food & Beverage$1,898 (5.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,853 | 10 | 64.6% |
| Travel and Lodging | $11,180 | 43 | 30.3% |
| Food and Beverage | $1,898 | 30 | 5.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BTG International, Inc. | $35,656 | 60 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $209.88 | 3 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $168.29 | 3 | $0 (2017) |
| Neurocrine BioSciences, Inc. | $128.28 | 1 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $127.80 | 3 | $0 (2020) |
| La Jolla Pharmaceutical Company | $121.69 | 2 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $110.92 | 1 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $109.54 | 2 | $0 (2017) |
| The Medicines Company | $93.74 | 1 | $0 (2017) |
| Chiesi USA, Inc. | $77.62 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,552 | 59 | BTG International, Inc. ($35,552) |
| 2023 | $255.16 | 3 | Neurocrine BioSciences, Inc. ($128.28) |
| 2022 | $104.28 | 1 | BTG International, Inc. ($104.28) |
| 2020 | $154.90 | 5 | La Jolla Pharmaceutical Company ($78.56) |
| 2019 | $299.07 | 4 | AstraZeneca Pharmaceuticals LP ($105.94) |
| 2018 | $193.57 | 5 | AstraZeneca Pharmaceuticals LP ($87.77) |
| 2017 | $371.57 | 6 | E.R. Squibb & Sons, L.L.C. ($168.29) |
All Payment Transactions
83 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | BTG International, Inc. | CROFAB (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,237.50 | General |
| Category: Anti-venom | ||||||
| 11/21/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $135.07 | General |
| Category: Anti-venom | ||||||
| 11/20/2024 | BTG International, Inc. | CROFAB (Drug) | Food and Beverage | In-kind items and services | $111.56 | General |
| Category: Anti-venom | ||||||
| 11/12/2024 | BTG International, Inc. | DIGIFab (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,362.50 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 11/09/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $307.22 | General |
| Category: Anti-venom | ||||||
| 11/08/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Anti-venom | ||||||
| 11/02/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $229.50 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 11/01/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $375.47 | General |
| Category: Anti-venom | ||||||
| 11/01/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $245.47 | General |
| Category: Anti-venom | ||||||
| 11/01/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $243.51 | General |
| Category: Anti-venom | ||||||
| 10/31/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Anti-venom | ||||||
| 10/31/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Anti-venom | ||||||
| 10/31/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Anti-venom | ||||||
| 10/31/2024 | BTG International, Inc. | CROFAB (Drug) | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| Category: Anti-venom | ||||||
| 10/29/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $808.82 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 10/28/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $110.00 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 10/28/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $35.00 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 10/03/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $124.55 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 10/03/2024 | BTG International, Inc. | DIGIFab (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 10/03/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $15.41 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 09/26/2024 | BTG International, Inc. | DIGIFab (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,450.00 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 09/25/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $526.20 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 09/21/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $973.50 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 09/19/2024 | BTG International, Inc. | DIGIFab (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $175.00 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
| 09/18/2024 | BTG International, Inc. | DIGIFab (Drug) | Travel and Lodging | Cash or cash equivalent | $353.96 | General |
| Category: Toxicity Antidote (Digoxin Toxicity) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 39 | 40 | $23,320 | $5,533 |
| 2020 | 2 | 38 | 38 | $27,850 | $4,836 |
Total Patients
77
Total Services
78
Medicare Billing
$10,369
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 39 | 40 | $23,320 | $5,533 | 23.7% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 27 | 27 | $20,071 | $3,769 | 18.8% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 11 | 11 | $7,779 | $1,067 | 13.7% |
About Lindsey Epperson
Lindsey Epperson is a Emergency Medicine healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2016. The National Provider Identifier (NPI) number assigned to this provider is 1790137560.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lindsey Epperson has received a total of $36,931 in payments from pharmaceutical and medical device companies, with $35,552 received in 2024. These payments were reported across 83 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,853).
As a Medicare-enrolled provider, Epperson has provided services to 77 Medicare beneficiaries, totaling 78 services with total Medicare billing of $10,369. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Location Oklahoma City, OK
- Active Since 07/05/2016
- Last Updated 07/05/2016
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1790137560
Products in Payments
- DIGIFab (Drug) $21,450
- DIGIFAB (Drug) $7,579
- CROFAB (Drug) $6,627
- ELIQUIS (Drug) $216.04
- RELISTOR (Drug) $127.80
- LOKELMA (Drug) $122.11
- GIAPREZA (Drug) $121.69
- Austedo XR (Drug) $110.92
- XIFAXAN (Drug) $109.54
- MINOCIN IV (Drug) $93.74
- BRILINTA (Drug) $87.77
- CLEVIPREX (Drug) $60.39
- XARELTO (Drug) $34.62
- CARDENE (Drug) $17.23
- LifeVest (Device) $16.08
- ANAVIP (Biological) $15.96
- CHANTIX (Drug) $12.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Oklahoma City
Alexander Frank, M.d, M.D
Emergency Medicine — Payments: $3.1M
Emergency Medicine $3.1M
Mohammad Razaq, M.d, M.D
Emergency Medicine — Payments: $177,813
Emergency Medicine $177,813
Jose Borrego Acosta, Md, MD
Emergency Medicine — Payments: $76,213
Emergency Medicine $76,213
Dr. Tyson Quy, M.d, M.D
Emergency Medicine — Payments: $35,983
Emergency Medicine $35,983
Michael Partin, M.d, M.D
Emergency Medicine — Payments: $10,117
Emergency Medicine $10,117
Dr. Corey Finch, Md, MD
Emergency Medicine — Payments: $5,461
Emergency Medicine $5,461